Related Experiment Video

Updated: Oct 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN

Minami Omura1, Takeo Kosaka1, Eriko Aimono2

  • 1Department of Urology Keio University School of Medicine Tokyo Japan.

IJU Case Reports
|January 10, 2022
PubMed
Abstract

Insights

Advanced prostate cancer with BRCA2 and PTEN mutations responded well to platinum therapy. This case highlights the importance of genetic profiling for guiding treatment decisions in complex cancer cases.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Deoxyribonucleic acid (DNA) repair gene mutations are increasingly investigated in solid tumors.
  • The goal is to predict prognosis, pathogenesis, and treatment outcomes.

Observation:

  • A Japanese patient with advanced castration-resistant prostate cancer was analyzed.
  • The patient had coexisting BRCA2 and PTEN mutations.

Findings:

  • The patient exhibited a prominent response to platinum therapy.
  • Multigene panel analysis confirmed the BRCA2 and PTEN mutations.

Implications:

  • This case offers insights into managing prostate cancer based on tumor genetic status.
  • Genetic profiling may inform future treatment strategies for similar cases.
Keywords:
BRCA2 mutationDNA repaircase reportprognosistreatment outcome

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K